Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A11QVV0
Wed, 06.11.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma: Promising New Clinical Data on Lead ADC-Candidate HDP-101 to be Presented at ASH Annual Meeting 2024
Ladenburg, Germany, 6 November 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage developer of innovative Antibody Drug Conjugates (ADCs), today announces that new clinical data on its lead Amanitin-based AD [ … ]
Thu, 24.10.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma to Participate in Leading Scientific and Financial Conferences in November 2024
Ladenburg, Germany, 24 October 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage developer of innovative Antibody Drug Conjugates (ADCs), announces it will present its ADC candidates and ADC technology platforms at leading scien [ … ]
Thu, 10.10.2024
Heidelberg Pharma AG
Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2024
HDP-101 clinical trial in Europe and US continues with adjusted protocol and dose optimization on track; sixth patient cohort dosed at 90 µg/kg and patients are still on treatment
Sale of a portion of future royalties for TLX250-CDx to HealthCare Royalty
New cli [ … ]
Tue, 01.10.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma: New Clinical Data on Lead ADC Candidate HDP-101 Presented at IMS 2024 Demonstrating Complete Remission in One Patient
Data from the study with the lead ADC candidate, HDP-101, show elimination of tumor cells in one patient
Clinical data from IMS will be presented in R&D webinar on 15 October at 17:00 CEST / 1 [ … ]
Mon, 23.09.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2024
Ladenburg, Germany, 23 September 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), today announces that new data from [ … ]
Mon, 23.09.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2024
Ladenburg, Germany, 23 September 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), today announces that new data from [ … ]
Thu, 11.07.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Reports on First Half-Year 2024 and the Course of Business
First preliminary efficacy data from the clinical trial with HDP-101 in multiple myeloma published
Presentation of preclinical and clinical data of the proprietary ADC technology platforms at the AACR Meeting 2024
HDP-101 granted Orphan Drug Designation [ … ]
Fri, 21.06.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma reports on the results of the Annual General Meeting 2024
Ladenburg, Germany, 21 June 2024 – Heidelberg Pharma AG (FSE: HPHA) announced that the company's shareholders approved the following proposed resolutions of the management with a large majority (between 98,35% and 99,99%) at yesterday's ordinary virtual Annu [ … ]
Thu, 23.05.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024
Ladenburg, Germany, 23 May 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that its management team will be participating [ … ]
Thu, 23.05.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024
Ladenburg, Germany, 23 May 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that its management team will be participating [ … ]